메뉴 건너뛰기




Volumn 27, Issue 2, 2015, Pages 123-129

Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients

Author keywords

hepatitis C virus; HIV; protease inhibitor; veterans

Indexed keywords

ATAZANAVIR; BOCEPREVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; LOPINAVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; TELAPREVIR; TENOFOVIR; ANTIVIRUS AGENT; INTERFERON; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE;

EID: 84920285596     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000241     Document Type: Article
Times cited : (6)

References (22)
  • 1
    • 0037087144 scopus 로고    scopus 로고
    • Hepatitis c virus prevalence among patients infected with human immunodeficiency virus: A crosssectional analysis of the us adult aids clinical trials group
    • Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a crosssectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837
    • (2002) Clin Infect Dis , vol.34 , pp. 831-837
    • Sherman, K.E.1    Rouster, S.D.2    Chung, R.T.3    Rajicic, N.4
  • 2
    • 3343012408 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for chronic hepatitis c virus infection in hiv-infected patients
    • APRICOT Study Group
    • Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al. APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450
    • (2004) N Engl J Med , vol.351 , pp. 438-450
    • Torriani, F.J.1    Rodriguez-Torres, M.2    Rockstroh, J.K.3    Lissen, E.4    Gonzalez-García, J.5    Lazzarin, A.6
  • 3
    • 3342892905 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis c in hiv-coinfected persons
    • Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459
    • (2004) N Engl J Med , vol.351 , pp. 451-459
    • Chung, R.T.1    Andersen, J.2    Volberding, P.3    Robbins, G.K.4    Liu, T.5    Sherman, K.E.6
  • 4
    • 84879799809 scopus 로고    scopus 로고
    • Combination therapy with telaprevir for chronic hepatitis c virus genotype 1 infection in patients with hiv: A randomized trial
    • Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159:86-96
    • (2013) Ann Intern Med , vol.159 , pp. 86-96
    • Sulkowski, M.S.1    Sherman, K.E.2    Dieterich, D.T.3    Bsharat, M.4    Mahnke, L.5    Rockstroh, J.K.6
  • 5
    • 84879795434 scopus 로고    scopus 로고
    • Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis c virus genotype 1 in patients with hiv: A randomised, double-blind, controlled phase 2 trial
    • Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13:597-605
    • (2013) Lancet Infect Dis , vol.13 , pp. 597-605
    • Sulkowski, M.1    Pol, S.2    Mallolas, J.3    Fainboim, H.4    Cooper, C.5    Slim, J.6
  • 6
    • 84891835213 scopus 로고    scopus 로고
    • Virological response rates for telaprevir-based hepatitis c triple therapy in patients with and without hiv coinfection
    • Martel-Laferrière V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, et al. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med 2014; 15:108-115
    • (2014) HIV Med , vol.15 , pp. 108-115
    • Martel-Laferrière, V.1    Brinkley, S.2    Bichoupan, K.3    Posner, S.4    Stivala, A.5    Perumalswami, P.6
  • 9
    • 13744255153 scopus 로고    scopus 로고
    • The effect of hiv coinfection on the risk of cirrhosis and hepatocellular carcinoma in us veterans with hepatitis c
    • Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005; 100:56-63
    • (2005) Am J Gastroenterol , vol.100 , pp. 56-63
    • Kramer, J.R.1    Giordano, T.P.2    Souchek, J.3    Richardson, P.4    Hwang, L.Y.5    El-Serag, H.B.6
  • 11
    • 79551648518 scopus 로고    scopus 로고
    • Utilization of surveillance for hepatocellular carcinoma among hepatitis c virus-infected veterans in the united states
    • Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, El-Serag HB. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011; 154:85-93
    • (2011) Ann Intern Med , vol.154 , pp. 85-93
    • Davila, J.A.1    Henderson, L.2    Kramer, J.R.3    Kanwal, F.4    Richardson, P.A.5    Duan, Z.6    El-Serag, H.B.7
  • 12
    • 84872144438 scopus 로고    scopus 로고
    • The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection
    • Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013; 57:249-257
    • (2013) Hepatology , vol.57 , pp. 249-257
    • Ioannou, G.N.1    Bryson, C.L.2    Weiss, N.S.3    Miller, R.4    Scott, J.D.5    Boyko, E.J.6
  • 14
    • 34547483053 scopus 로고    scopus 로고
    • FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest
    • Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46:32-36
    • (2007) Hepatology , vol.46 , pp. 32-36
    • Vallet-Pichard, A.1    Mallet, V.2    Nalpas, B.3    Verkarre, V.4    Nalpas, A.5    Dhalluin-Venier, V.6
  • 15
    • 12444311293 scopus 로고    scopus 로고
    • Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis c
    • Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 2003; 39:106-111
    • (2003) J Hepatol , vol.39 , pp. 106-111
    • Zeuzem, S.1    Heathcote, E.J.2    Shiffman, M.L.3    Wright, T.L.4    Bain, V.G.5    Sherman, M.6
  • 16
    • 84904393872 scopus 로고    scopus 로고
    • Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis c virus infection on the basis of a nationwide study of veterans
    • Ioannou GN, Beste LA, Green PK. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans. Clin Gastroenterol Hepatol 2014; 12:1371-1380
    • (2014) Clin Gastroenterol Hepatol , vol.12 , pp. 1371-1380
    • Ioannou, G.N.1    Beste, L.A.2    Green, P.K.3
  • 17
    • 84893648933 scopus 로고    scopus 로고
    • Rates and predictors of response to anti-viral treatment for hepatitis c virus in hiv/hcv co-infection in a nationwide study of 619 patients
    • Ioannou GN, Scott JD, Yang Y, Green PK, Beste LA. Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients. Aliment Pharmacol Ther 2013; 38:1373-1384
    • (2013) Aliment Pharmacol Ther , vol.38 , pp. 1373-1384
    • Ioannou, G.N.1    Scott, J.D.2    Yang, Y.3    Green, P.K.4    Beste, L.A.5
  • 18
    • 34547428001 scopus 로고    scopus 로고
    • Predictors of response of us veterans to treatment for the hepatitis c virus
    • Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46:37-47
    • (2007) Hepatology , vol.46 , pp. 37-47
    • Backus, L.I.1    Boothroyd, D.B.2    Phillips, B.R.3    Mole, L.A.4
  • 19
    • 84892737595 scopus 로고    scopus 로고
    • All-oral therapy with sofosbuvir plus ribavirin for the treatment of hcv genotype 1, 2, and 3 infection in patients co-infected with hiv (photon-1) [abstract 212
    • AASLD 2013); Washington DC
    • Sulkowski MS, Rodriguez-Torres M, Lalezari JP. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1) [Abstract 212]. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013); Washington, DC, 2013
    • (2013) 64th Annual Meeting of the American Association for the Study of Liver Diseases
    • Sulkowski, M.S.1    Rodriguez-Torres, M.2    Lalezari, J.P.3
  • 20
    • 84878976866 scopus 로고    scopus 로고
    • Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis c genotype-1 infection (atomic): An open-label, randomised, multicentre phase 2 trial
    • Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381:2100-2107
    • (2013) Lancet , vol.381 , pp. 2100-2107
    • Kowdley, K.V.1    Lawitz, E.2    Crespo, I.3    Hassanein, T.4    Davis, M.N.5    Demicco, M.6
  • 21
    • 84876740954 scopus 로고    scopus 로고
    • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis c infection: A randomised, double-blind, phase 2 trial
    • Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13:401-408
    • (2013) Lancet Infect Dis , vol.13 , pp. 401-408
    • Lawitz, E.1    Lalezari, J.P.2    Hassanein, T.3    Kowdley, K.V.4    Poordad, F.F.5    Sheikh, A.M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.